Freeline Therapeutics Holdings Stock Beta
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Freeline Therapeutics Holdings fundamentals help investors to digest information that contributes to Freeline Therapeutics' financial success or failures. It also enables traders to predict the movement of Freeline Stock. The fundamental analysis module provides a way to measure Freeline Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Freeline Therapeutics stock.
Freeline |
Freeline Therapeutics Holdings Company Beta Analysis
Freeline Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Freeline Therapeutics Beta | 0.66 |
Most of Freeline Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Freeline Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Freeline Therapeutics Holdings has a Beta of 0.66. This is 23.26% lower than that of the Biotechnology sector and 52.52% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Freeline Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Freeline Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Freeline Therapeutics could also be used in its relative valuation, which is a method of valuing Freeline Therapeutics by comparing valuation metrics of similar companies.Freeline Therapeutics is currently under evaluation in beta category among its peers.
As returns on the market increase, Freeline Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Freeline Therapeutics is expected to be smaller as well.
Freeline Fundamentals
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | 2.78 M | |||
| Shares Outstanding | 4.36 M | |||
| Shares Owned By Insiders | 1.09 % | |||
| Shares Owned By Institutions | 45.88 % | |||
| Number Of Shares Shorted | 23.93 K | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 45.40 X | |||
| Revenue | 622 K | |||
| EBITDA | (64.84 M) | |||
| Net Income | (49.93 M) | |||
| Cash And Equivalents | 90 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 5.92 M | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 6.89 X | |||
| Cash Flow From Operations | (64.24 M) | |||
| Short Ratio | 1.92 X | |||
| Earnings Per Share | (11.40) X | |||
| Target Price | 8.25 | |||
| Number Of Employees | 152 | |||
| Beta | 0.66 | |||
| Market Capitalization | 28.24 M | |||
| Total Asset | 86.64 M | |||
| Retained Earnings | (445.35 M) | |||
| Working Capital | 36.66 M | |||
| Z Score | -6.29 | |||
| Net Asset | 86.64 M |
About Freeline Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Freeline Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Freeline Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Freeline Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Freeline Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Freeline Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Freeline Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Freeline Stock
| 0.7 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.64 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.56 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.35 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.34 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
The ability to find closely correlated positions to Freeline Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Freeline Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Freeline Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Freeline Therapeutics Holdings to buy it.
The correlation of Freeline Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Freeline Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Freeline Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Freeline Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |